Hepatocellular carcinoma RFA
Conditions
Interventions
Radiofrequency ablation, Durvalumab plus Tremelimumab
Sponsors
Yamashita Taro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 18 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
Exclusion criteria
Exclusion criteria: 1) Active double cancer 2) Receiving any combination of chemotherapy, investigational drugs, and biologic or hormonal therapy for the treatment of cancer 3) With previous radiotherapy 4) Active infection 5) Fever of 38 degrees Celsius or higher 6) Active autoimmune or inflammatory disease or a confirmed history of such disease 7) Taking antiplatelet or anticoagulant medication 8) Complicated by one or more of interstitial pneumonia, pulmonary fibrosis, or severe emphysema 9) Unhealed fistulas, ulcerative lesions, and active bleeding 10) Metastases to central nervous system 11) Moderate or severe ascites and/or pleural effusion 12) Severe complication 13) Poorly controlled diabetes 14) Pregnant or lactating women 15) Mental disorder 16) Patients who investigator regards as inappropriate for candidate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Objective response rate, Tumor control rate, Subsequent therpay, Severe adverse events | — |
Contacts
Public ContactTakeshi Terashima
Kanazawa Medical University Hospital
Outcome results
None listed